AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.67-1.84 (-1.74%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.67-1.84 (-1.74%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|
8.8 C
New York
Sunday, November 1, 2026

Tag: source

PFMCrypto Launches Revolutionary XRP Mining Contracts, Igniting Market Enthusiasm

PFMCrypto’s bold move has attracted the attention of cryptocurrency enthusiasts worldwide with the launch of a revolutionary XRP mining model—potentially marking a turning point for the digital asset. As XRP continues to consolidate, analysts suggest that a breakout may be imminent
PFMCrypto’s bold move has attracted the attention of cryptocurrency enthusiasts worldwide with the launch of a revolutionary XRP mining model—potentially marking a turning point for the digital asset. As XRP continues to consolidate, analysts suggest that a breakout may be imminent

RCAT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action...

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Red Cat Holdings, Inc. (“Red Cat” or “the Company”) (NASDAQ: RCAT) and certain of its officers.

BITF INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bitfarms Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bitfarms Ltd. (“Bitfarms” or “the Company”) (NASDAQ: BITF) and certain of its officers.

DMRC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Digimarc Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Digimarc Corporation (“Digimarc” or “the Company”) (NASDAQ: DMRC) and certain of its officers.

KANEKA UBIQUINOL™ WINS COVETED MARKETING AWARD 2025 AT NATURAL HEALTH PRODUCTS NEW ZEALAND SUMMIT

SYDNEY, June 23, 2025 /PRNewswire/ -- Kaneka Corporation Supplement Division APAC, the world-renowned manufacturer and global supplier of Ubiquinol is thrilled to announce that...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Revolutionary Research by Dr. Takuma Hayashi Uncovers Molecular Origins of Deadly Uterine Cancer and Charts New Path for Treatment

In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

Findings Highlight Potential for Novel Approach to Insulin Delivery in Pediatric Population CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin...

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTRE

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline.

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Red Cat Holdings, Inc. (RCAT) Investors with Substantial Losses Have Opportunity to Lead Investor...

SAN DIEGO, June 22, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025, inclusive (the “Class Period”), have until Tuesday, July 22, 2025 to seek appointment as lead plaintiff of the Red Cat class action lawsuit. Captioned Olsen v. Red Cat Holdings, Inc., No. 25-cv-05427 (D.N.J.), the Red Cat class action lawsuit charges Red Cat as well as certain of Red Cat’s top current and former executives with violations of the Securities Exchange Act of 1934.

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSource